Drug Profile
PAT SC1
Alternative Names: PAT-SC1; SC-1Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator OncoMab GmbH
- Developer Patrys
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Gastric cancer
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Gastric-cancer in China (IV, Infusion)
- 13 Sep 2016 Preclinical trials in Gastric cancer in China (IV)
- 22 Sep 2015 PAT SC1 completes phase-I/II development for Gastric cancer in Germany